Raymond U Osarogiagbon1, Helmneh M Sineshaw2, Chun Chieh Lin2, Ahmedin Jemal2. 1. Thoracic Oncology Research Group, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN. Electronic address: rosarogi@bmhcc.org. 2. Surveillance and Health Services Research Program, American Cancer Society, Atlanta, GA.
Abstract
BACKGROUND: Institutional-level disparities in non-small cell lung cancer (NSCLC) survival may be driven by reversible differences in care-delivery processes. We quantified the impact of differences in readily identifiable quality metrics on long-term survival disparities in resected NSCLC. RESEARCH QUESTION: How do reversible differences in oncologic quality of care contribute to institutional-level disparities in early-stage NSCLC survival? STUDY DESIGN AND METHODS: We retrospectively analyzed patients in the National Cancer Data Base who underwent NSCLC resection from 2004 through 2015 within institutions categorized as Community, Comprehensive Community, Integrated Network, Academic, and National Cancer Institute (NCI)-Designated Cancer Programs. We estimated percentages and adjusted ORs for six potentially avoidable poor-quality markers: incomplete resection, nonexamination of lymph nodes, nonanatomic resection, non-evidence-based use of adjuvant chemotherapy, non-evidence-based use of adjuvant radiation therapy, and 60-day postoperative mortality. By sequentially eliminating patients with poor-quality markers and calculating adjusted hazard ratios, we quantified their overall survival impact. RESULTS: Of 169,775 patients, 7%, 46%, 10%, 24%, and 12% underwent surgery at Community, Comprehensive Community, Integrated Network, Academic, and NCI-Designated Cancer Programs, with 5-year overall survival rates of 52%, 56%, 58%, 60% and 66%, respectively. After the sequential elimination process, using NCI-Designated Cancer Centers as a reference, the adjusted hazard ratio for 5-year overall survival changed from 1.47 (95% CI, 1.41-1.53), 1.29 (95% CI, 1.25-1.33), 1.18 (95% CI, 1.14-1.23), and 1.20 (95% CI, 1.16-1.24) for Community, Comprehensive Community, Integrated Networks, and Academic Cancer Programs to 1.35 (95% CI, 1.28-1.42), 1.22 (95% CI, 1.17-1.26), 1.16 (95% CI, 1.11-1.22), and 1.17 (95% CI, 1.12-1.21), respectively (P < .001 for all comparisons with NCI-designated programs). Differences in quality of surgical resection and postoperative care accounted for 11% to 26% of the interinstitutional survival disparities. INTERPRETATION: Targeting six readily identified poor-quality markers narrowed, but did not eliminate, institutional survival disparities. The greatest impact was in community programs. Residual factors driving persistent institution-level long-term NSCLC survival disparities must be characterized to eliminate them.
BACKGROUND: Institutional-level disparities in non-small cell lung cancer (NSCLC) survival may be driven by reversible differences in care-delivery processes. We quantified the impact of differences in readily identifiable quality metrics on long-term survival disparities in resected NSCLC. RESEARCH QUESTION: How do reversible differences in oncologic quality of care contribute to institutional-level disparities in early-stage NSCLC survival? STUDY DESIGN AND METHODS: We retrospectively analyzed patients in the National Cancer Data Base who underwent NSCLC resection from 2004 through 2015 within institutions categorized as Community, Comprehensive Community, Integrated Network, Academic, and National Cancer Institute (NCI)-Designated Cancer Programs. We estimated percentages and adjusted ORs for six potentially avoidable poor-quality markers: incomplete resection, nonexamination of lymph nodes, nonanatomic resection, non-evidence-based use of adjuvant chemotherapy, non-evidence-based use of adjuvant radiation therapy, and 60-day postoperative mortality. By sequentially eliminating patients with poor-quality markers and calculating adjusted hazard ratios, we quantified their overall survival impact. RESULTS: Of 169,775 patients, 7%, 46%, 10%, 24%, and 12% underwent surgery at Community, Comprehensive Community, Integrated Network, Academic, and NCI-Designated Cancer Programs, with 5-year overall survival rates of 52%, 56%, 58%, 60% and 66%, respectively. After the sequential elimination process, using NCI-Designated Cancer Centers as a reference, the adjusted hazard ratio for 5-year overall survival changed from 1.47 (95% CI, 1.41-1.53), 1.29 (95% CI, 1.25-1.33), 1.18 (95% CI, 1.14-1.23), and 1.20 (95% CI, 1.16-1.24) for Community, Comprehensive Community, Integrated Networks, and Academic Cancer Programs to 1.35 (95% CI, 1.28-1.42), 1.22 (95% CI, 1.17-1.26), 1.16 (95% CI, 1.11-1.22), and 1.17 (95% CI, 1.12-1.21), respectively (P < .001 for all comparisons with NCI-designated programs). Differences in quality of surgical resection and postoperative care accounted for 11% to 26% of the interinstitutional survival disparities. INTERPRETATION: Targeting six readily identified poor-quality markers narrowed, but did not eliminate, institutional survival disparities. The greatest impact was in community programs. Residual factors driving persistent institution-level long-term NSCLC survival disparities must be characterized to eliminate them.
Authors: Mark G Kris; Bruce E Johnson; Lynne D Berry; David J Kwiatkowski; A John Iafrate; Ignacio I Wistuba; Marileila Varella-Garcia; Wilbur A Franklin; Samuel L Aronson; Pei-Fang Su; Yu Shyr; D Ross Camidge; Lecia V Sequist; Bonnie S Glisson; Fadlo R Khuri; Edward B Garon; William Pao; Charles Rudin; Joan Schiller; Eric B Haura; Mark Socinski; Keisuke Shirai; Heidi Chen; Giuseppe Giaccone; Marc Ladanyi; Kelly Kugler; John D Minna; Paul A Bunn Journal: JAMA Date: 2014-05-21 Impact factor: 56.272
Authors: Matthew P Smeltzer; Chun Chieh Lin; Feng-Ming Spring Kong; Ahmedin Jemal; Raymond U Osarogiagbon Journal: J Thorac Cardiovasc Surg Date: 2017-04-04 Impact factor: 5.209
Authors: Meredith A Ray; Nicholas R Faris; Anna Derrick; Matthew P Smeltzer; Raymond U Osarogiagbon Journal: Chest Date: 2020-05-06 Impact factor: 9.410
Authors: Raymond U Osarogiagbon; Yu-Sheng Lee; Nicholas R Faris; Meredith A Ray; Philip O Ojeabulu; Matthew P Smeltzer Journal: J Thorac Cardiovasc Surg Date: 2019-05-02 Impact factor: 5.209
Authors: Ali H Mokdad; Laura Dwyer-Lindgren; Christina Fitzmaurice; Rebecca W Stubbs; Amelia Bertozzi-Villa; Chloe Morozoff; Raghid Charara; Christine Allen; Mohsen Naghavi; Christopher J L Murray Journal: JAMA Date: 2017-01-24 Impact factor: 56.272
Authors: Karl Y Bilimoria; David J Bentrem; Andrew K Stewart; David P Winchester; Clifford Y Ko Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544
Authors: Joseph M Unger; Anna Moseley; Banu Symington; Mariana Chavez-MacGregor; Scott D Ramsey; Dawn L Hershman Journal: JAMA Netw Open Date: 2018-08-03
Authors: Kenneth L Kehl; David Zahrieh; Ping Yang; Shauna L Hillman; Angelina D Tan; Jacob M Sands; Geoffrey R Oxnard; Erin A Gillaspie; Dennis Wigle; Shakun Malik; Thomas E Stinchcombe; Suresh S Ramalingam; Karen Kelly; Ramaswamy Govindan; Sumithra J Mandrekar; Raymond U Osarogiagbon; David Kozono Journal: JAMA Oncol Date: 2022-05-01 Impact factor: 33.006
Authors: Raymond U Osarogiagbon; Matthew P Smeltzer; Nicholas R Faris; Meredith A Ray; Carrie Fehnel; Phillip Ojeabulu; Olawale Akinbobola; Meghan Meadows-Taylor; Laura M McHugh; Ahmed M Halal; Paul Levy; Vishal Sachdev; David Talton; Lynn Wiggins; Xiao-Ou Shu; Yu Shyr; Edward T Robbins; Lisa M Klesges Journal: J Thorac Oncol Date: 2021-02-16 Impact factor: 15.609